scPharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	13.59	0	0	0	0	0	0	0	0
Cost of Revenue	3.81	0	0	0	0	0	0	0	0
Gross Profit	9.78	0	0	0	0	0	0	0	0
Selling, General & Admin	53.37	20.62	9.78	11.78	8.27	13.72	9.11	6.05	2.58
Research & Development	11.81	15.53	16.04	18.15	24.63	15.95	14.33	11.86	8.27
Operating Expenses	65.18	36.16	25.82	29.93	32.91	29.67	23.44	17.91	10.84
Operating Income	-55.4	-36.16	-25.82	-29.93	-32.91	-29.67	-23.44	-17.91	-10.84
Interest Expense / Income	8.12	3.3	2.58	2.59	1.77	1.43	0.8	6.51	0
Other Expense / Income	-8.71	-2.62	-0.36	-0.31	-1.68	-1.66	-0.42	-0.05	-0.33
Pretax Income	-54.81	-36.84	-28.03	-32.21	-33	-29.44	-23.82	-24.38	-10.52
Net Income	-54.81	-36.84	-28.03	-32.21	-33	-29.44	-23.82	-24.38	-10.52
Shares Outstanding (Basic)	39	28	27	25	19	19	3	1	1
Shares Outstanding (Diluted)	39	28	27	25	19	19	3	1	1
Shares Change	35.81%	3.68%	11.33%	32.09%	0.24%	526.29%	203.99%	27.72%	-
EPS (Basic)	-1.42	-1.30	-1.02	-1.31	-1.77	-1.59	-8.04	-25.01	-13.78
EPS (Diluted)	-1.42	-1.30	-1.02	-1.31	-1.77	-1.59	-8.04	-25.01	-13.78
Free Cash Flow	-59.28	-34.6	-27.16	-27.69	-30.44	-28.81	-22.88	-15.46	-9.66
Free Cash Flow Per Share	-1.54	-1.22	-0.99	-1.13	-1.64	-1.55	-7.72	-15.87	-12.65
Gross Margin	71.96%	-	-	-	-	-	-	-	-
Operating Margin	-407.53%	-	-	-	-	-	-	-	-
Profit Margin	-403.22%	-	-	-	-	-	-	-	-
Free Cash Flow Margin	-436.14%	-	-	-	-	-	-	-	-
EBITDA	-46.06	-33.07	-25.02	-29.22	-30.87	-27.68	-23	-17.86	-10.51
EBITDA Margin	-338.86%	-	-	-	-	-	-	-	-
Depreciation & Amortization	0.63	0.47	0.44	0.4	0.36	0.33	0.02	0.01	0
EBIT	-46.69	-33.54	-25.46	-29.62	-31.23	-28.01	-23.02	-17.87	-10.52
EBIT Margin	-343.46%	-	-	-	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).